AVTE Nov 2024 25.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 11:43AM EDT
Loading interactive chart…
- Zacks
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals
Aerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients.
- Barrons.com
Aerovate Therapeutics Stock Dropped Over 90%. Here’s Why.
The company said its blood pressure drug failed in Phase 2 testing. The drug is its sole asset, according to Jefferies analysts.
- Investor's Business Daily
Why 93% Of Aerovate Therapeutics' Value Just Went Up In Smoke
Aerovate Therapeutics said Monday its experimental blood pressure medicine failed in Phase 2 testing, and the biotech stock plummeted 93%.
© 2024 Yahoo. All rights reserved.